AU2014256037B2 - Novel bispecific binding molecules with antitumoral activity - Google Patents

Novel bispecific binding molecules with antitumoral activity Download PDF

Info

Publication number
AU2014256037B2
AU2014256037B2 AU2014256037A AU2014256037A AU2014256037B2 AU 2014256037 B2 AU2014256037 B2 AU 2014256037B2 AU 2014256037 A AU2014256037 A AU 2014256037A AU 2014256037 A AU2014256037 A AU 2014256037A AU 2014256037 B2 AU2014256037 B2 AU 2014256037B2
Authority
AU
Australia
Prior art keywords
seq
antibody
cancer
polypeptides
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014256037A
Other languages
English (en)
Other versions
AU2014256037A1 (en
Inventor
Isabella Attinger-Toller
Julian Bertschinger
Simon Brack
Fabian Buller
Dragan Grabulovski
Helen HACHEMI
Patricia Henne
Kristina KLUPSCH
Susann Konig-Friedrich
Roger Santimaria
Michela Silacci
Ulrike Von Der Bey
Richard Woods
Ulrich Wullner
Irene Zbinden
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cilag GmbH International
Original Assignee
Covagen AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Covagen AG filed Critical Covagen AG
Publication of AU2014256037A1 publication Critical patent/AU2014256037A1/en
Application granted granted Critical
Publication of AU2014256037B2 publication Critical patent/AU2014256037B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10002—Non-specific protein-tyrosine kinase (2.7.10.2), i.e. spleen tyrosine kinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
AU2014256037A 2013-04-19 2014-03-06 Novel bispecific binding molecules with antitumoral activity Ceased AU2014256037B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13164555 2013-04-19
EP13164555.8 2013-04-19
PCT/EP2014/054390 WO2014170063A1 (en) 2013-04-19 2014-03-06 Novel bispecific binding molecules with antitumoral activity

Publications (2)

Publication Number Publication Date
AU2014256037A1 AU2014256037A1 (en) 2015-10-29
AU2014256037B2 true AU2014256037B2 (en) 2017-09-21

Family

ID=48128216

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014256037A Ceased AU2014256037B2 (en) 2013-04-19 2014-03-06 Novel bispecific binding molecules with antitumoral activity

Country Status (15)

Country Link
EP (1) EP2986630B1 (enExample)
JP (2) JP6694808B2 (enExample)
KR (1) KR20160002882A (enExample)
CN (1) CN105189544A (enExample)
AU (1) AU2014256037B2 (enExample)
BR (1) BR112015026143A2 (enExample)
CA (1) CA2908988A1 (enExample)
CL (1) CL2015003085A1 (enExample)
EA (1) EA201592006A1 (enExample)
HK (1) HK1214605A1 (enExample)
MX (1) MX2015014608A (enExample)
PH (1) PH12015502278A1 (enExample)
SG (1) SG11201508231UA (enExample)
WO (1) WO2014170063A1 (enExample)
ZA (1) ZA201507752B (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
ES2984771T3 (es) 2012-06-13 2024-10-31 Incyte Holdings Corp Compuestos tricíclicos sustituidos como inhibidores de FGFR
EA035095B1 (ru) 2013-04-19 2020-04-27 Инсайт Холдингс Корпорейшн Бициклические гетероциклы в качестве ингибиторов fgfr
CN112390883A (zh) 2013-12-17 2021-02-23 基因泰克公司 抗cd3抗体及使用方法
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
EA038045B1 (ru) 2015-02-20 2021-06-28 Инсайт Корпорейшн Бициклические гетероциклы в качестве ингибиторов fgfr
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016204966A1 (en) 2015-06-16 2016-12-22 Genentech, Inc. Anti-cd3 antibodies and methods of use
FI126633B (en) 2015-07-10 2017-03-15 Next Biomed Therapies Oy Method for the preparation of a library of derivatives of the SH3 domain of recombinant nephrocystin (NPHP1)
US12128102B2 (en) 2016-03-08 2024-10-29 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
KR20190074300A (ko) 2016-11-15 2019-06-27 제넨테크, 인크. 항-cd20/항-cd3 이중특이적 항체에 의한 치료를 위한 투약
US10722589B2 (en) 2017-04-03 2020-07-28 Covagen Ag FGFR3 binding molecules
MX2019012606A (es) * 2017-04-24 2019-12-02 Ichnos Sciences SA Celulas t que redirigen anticuerpos biespecificos para el tratamiento de canceres positivos a egfr.
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
WO2019033050A1 (en) * 2017-08-11 2019-02-14 City Of Hope BISPECIFIC MOLECULE FOR BINDING TO ANTIGEN
AU2018314236B2 (en) 2017-08-11 2025-02-06 Apterna Limited RNA aptamers against transferrin receptor (TfR)
EP3679068A2 (en) * 2017-09-08 2020-07-15 Maverick Therapeutics, Inc. CONDITIONALLY ACTIVATED BINDING MOIETIES CONTAINING Fc REGIONS
KR20240170847A (ko) 2017-09-08 2024-12-04 다케다 야쿠힌 고교 가부시키가이샤 제약된 조건적으로 활성화된 결합 단백질
US20190153096A1 (en) 2017-10-02 2019-05-23 Covagen Ag Cd3/cd33 bispecific binding molecules
US20190100587A1 (en) * 2017-10-02 2019-04-04 Covagen Ag IgG1 Fc MUTANTS WITH ABLATED EFFECTOR FUNCTIONS
CA3089287A1 (en) 2018-02-08 2019-08-15 Genentech, Inc. Bispecific antigen-binding molecules and methods of use
RS66310B1 (sr) 2018-05-04 2025-01-31 Incyte Corp Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu
US11174257B2 (en) 2018-05-04 2021-11-16 Incyte Corporation Salts of an FGFR inhibitor
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
PH12022550892A1 (en) 2019-10-14 2023-05-03 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
AU2020395185A1 (en) 2019-12-04 2022-06-02 Incyte Corporation Derivatives of an FGFR inhibitor
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CA3164226A1 (en) 2019-12-11 2021-06-17 Cilag Gmbh International Multispecific binding molecules comprising ltbr and edb binding domains and uses thereof
AR120741A1 (es) 2019-12-13 2022-03-16 Genentech Inc Anticuerpos anti-ly6g6d y métodos de uso
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
IL302396A (en) 2020-11-04 2023-06-01 Genentech Inc Dosage for treatment with bispecific anti-CD20/anti-CD3 antibodies
JP7716473B2 (ja) 2020-11-04 2025-07-31 ジェネンテック， インコーポレイテッド 抗ｃｄ２０／抗ｃｄ３二重特異性抗体の皮下投薬
JP2024513575A (ja) 2021-04-12 2024-03-26 インサイト・コーポレイション Ｆｇｆｒ阻害剤及びネクチン－４標的化剤を含む併用療法
AU2022273541A1 (en) 2021-05-14 2023-11-30 Genentech, Inc. Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
TW202313610A (zh) 2021-06-09 2023-04-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之三環雜環
WO2022261160A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US20250223376A1 (en) 2021-09-20 2025-07-10 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
US20250034559A1 (en) 2021-11-17 2025-01-30 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
AR129061A1 (es) 2022-04-13 2024-07-10 Genentech Inc Composiciones farmacéuticas de mosunetuzumab y métodos de uso
WO2023220695A2 (en) 2022-05-13 2023-11-16 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2025221728A2 (en) 2024-04-15 2025-10-23 Janssen Biotech, Inc. Ltbr binding molecules and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1892248A1 (en) * 2006-08-21 2008-02-27 Eidgenössische Technische Hochschule Zürich Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase
CN102869678A (zh) * 2009-08-27 2013-01-09 科瓦根股份公司 Il-17结合化合物及其医药用途
WO2011116387A1 (en) * 2010-03-19 2011-09-22 Tetragenetics, Inc. Production of aglycosylated monoclonal antibodies in ciliates
WO2011147986A1 (en) * 2010-05-27 2011-12-01 Genmab A/S Monoclonal antibodies against her2

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HUI REN ET AL, ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, (20120630), vol. 13, no. 6, doi:10.7314/APJCP.2012.13.6.2795, ISSN 1513-7368, pages 2795 - 2798 *

Also Published As

Publication number Publication date
JP2016516789A (ja) 2016-06-09
KR20160002882A (ko) 2016-01-08
JP2019106997A (ja) 2019-07-04
HK1214605A1 (zh) 2016-07-29
JP6694808B2 (ja) 2020-05-20
EP2986630A1 (en) 2016-02-24
MX2015014608A (es) 2016-03-03
PH12015502278A1 (en) 2016-02-01
EP2986630B1 (en) 2018-08-15
CN105189544A (zh) 2015-12-23
SG11201508231UA (en) 2015-11-27
CA2908988A1 (en) 2014-10-23
EA201592006A1 (ru) 2016-03-31
BR112015026143A2 (pt) 2017-10-17
ZA201507752B (en) 2017-03-29
WO2014170063A1 (en) 2014-10-23
CL2015003085A1 (es) 2016-06-03
AU2014256037A1 (en) 2015-10-29

Similar Documents

Publication Publication Date Title
AU2014256037B2 (en) Novel bispecific binding molecules with antitumoral activity
AU2021218004B2 (en) Constructs having a SIRP-alpha domain or variant thereof
CN113301919B (zh) 激活免疫细胞的双特异性抗体
ES2910365T3 (es) Nuevos polipéptidos biespecíficos contra CD137
KR101721301B1 (ko) 이중특이적 항원 결합 분자
JP2022514343A (ja) 腫瘍標的化アゴニストｃｄ２８抗原結合分子
TW201815820A (zh) 雙特異性t細胞活化抗原結合分子
US20240383978A1 (en) Bispecific binding proteins that bind cd137 and a tumor associated antigen
US12122845B2 (en) Anti-HER2/anti-4-1BB bispecific antibodies and uses thereof
EP4613774A1 (en) Single domain antibody targeting human ror1
WO2024140925A1 (en) Anti-b7h3 antibodies and methods of use
RU2832669C2 (ru) Антитела, связывающиеся с cd3
RU2826084C2 (ru) МОЛЕКУЛЫ АНТИТЕЛА, КОТОРЫЕ СВЯЗЫВАЮТ PD-L1 и CD137
RU2815176C2 (ru) Антитела, связывающиеся с hla-a2/wt1
HK40064097A (en) Constructs having a sirp-alpha domain or variant thereof
WO2025240670A2 (en) Anti-pd-1 antibodies and related binding molecules and methods and uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired